IPSOGEN, a leading provider of molecular diagnostic tests for the disease management of cancer patients, announced the signing of an agreement with Laboratory Corporation of America® Holdings (LabCorp, NYSE: LH) under which LabCorp will offer a JAK2 molecular diagnostic assay in the USA.
